These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 30968600)

  • 1. Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population-based cohort study.
    Kuo YJ; Sung FC; Hsieh PF; Chang HP; Wu KL; Wu HC
    Cancer Med; 2019 May; 8(5):2514-2523. PubMed ID: 30968600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan.
    Tseng CH
    BMC Cancer; 2013 Jan; 13():7. PubMed ID: 23286275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin and the risk of prostate cancer across racial/ethnic groups: a population-based cohort study.
    Chen CB; Eurich DT; Majumdar SR; Johnson JA
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):122-126. PubMed ID: 28071672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin use and long-term risk of benign prostatic hyperplasia: a population-based cohort study.
    Nørgaard M; Darvalics B; Thomsen RW
    BMJ Open; 2020 Dec; 10(12):e041875. PubMed ID: 33371039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The preventive effect of metformin on progression of benign prostate hyperplasia: A nationwide population-based cohort study in Korea.
    Hong Y; Lee S; Won S
    PLoS One; 2019; 14(7):e0219394. PubMed ID: 31323022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic interaction of benign prostatic hyperplasia and prostatitis on prostate cancer risk.
    Hung SC; Lai SW; Tsai PY; Chen PC; Wu HC; Lin WH; Sung FC
    Br J Cancer; 2013 May; 108(9):1778-83. PubMed ID: 23612451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Erectile Dysfunction and Subsequent Prostate Cancer Development: A Population-Based Cohort Study With Double Concurrent Comparison Groups.
    Kok VC; Hsiao YH; Horng JT; Wang KL
    Am J Mens Health; 2018 Sep; 12(5):1492-1502. PubMed ID: 29708021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer.
    Häggström C; Van Hemelrijck M; Zethelius B; Robinson D; Grundmark B; Holmberg L; Gudbjörnsdottir S; Garmo H; Stattin P
    Int J Cancer; 2017 Feb; 140(3):611-617. PubMed ID: 27770555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperthyroidism is not a significant risk of benign prostatic hyperplasia: A nationwide population-based study.
    Man KM; Chen KB; Chen HY; Chiang JH; Su YC; Man SS; Xie DD; Wang Y; Zhang ZQ; Bi LK; Zhang T; Yu DX; Chen WC
    Medicine (Baltimore); 2018 Sep; 97(39):e12459. PubMed ID: 30278528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidiabetic Drugs and Prostate Cancer Prognosis in a Finnish Population-Based Cohort.
    Vihervuori VJ; Talala K; Taari K; Lahtela J; Tammela TLJ; Auvinen A; Raittinen P; Murtola TJ
    Cancer Epidemiol Biomarkers Prev; 2021 May; 30(5):982-989. PubMed ID: 33653815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperlipidemia is associated with an increased risk of clinical benign prostatic hyperplasia.
    Shih HJ; Huang CJ; Lin JA; Kao MC; Fan YC; Tsai PS
    Prostate; 2018 Feb; 78(2):113-120. PubMed ID: 29119583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin and the incidence of prostate cancer in patients with type 2 diabetes.
    Azoulay L; Dell'Aniello S; Gagnon B; Pollak M; Suissa S
    Cancer Epidemiol Biomarkers Prev; 2011 Feb; 20(2):337-44. PubMed ID: 21148757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia.
    Nygård LH; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ
    Prostate; 2023 Feb; 83(3):246-258. PubMed ID: 36325820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus.
    Tseng CH
    Eur J Cancer; 2014 Nov; 50(16):2831-7. PubMed ID: 25201464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
    Schenk JM; Calip GS; Tangen CM; Goodman P; Parsons JK; Thompson IM; Kristal AR
    Am J Epidemiol; 2012 Jul; 176(2):156-63. PubMed ID: 22759721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate Cancer Patients With Unmanaged Diabetes or Receiving Insulin Experience Inferior Outcomes and Toxicities After Treatment With Radiation Therapy.
    Zaorsky NG; Shaikh T; Ruth K; Sharda P; Hayes SB; Sobczak ML; Hallman MA; Smaldone MC; Chen DY; Horwitz EM
    Clin Genitourin Cancer; 2017 Apr; 15(2):326-335.e3. PubMed ID: 27789181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus.
    Qiu H; Rhoads GG; Berlin JA; Marcella SW; Demissie K
    Diabetes Obes Metab; 2013 Apr; 15(4):349-57. PubMed ID: 23137378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study.
    Lin E; Garmo H; Van Hemelrijck M; Adolfsson J; Stattin P; Zethelius B; Crawley D
    BMC Cancer; 2020 Jun; 20(1):551. PubMed ID: 32539807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer.
    Hammarsten J; Högstedt B
    Blood Press; 2004; 13(1):47-55. PubMed ID: 15083641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.